{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:43:49Z","timestamp":1789879429469,"version":"4.0.1"},"reference-count":33,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2018,12,23]]},"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>The 3-min constant speed shuttle test (CSST) was used to examine the effect of tiotropium\/olodaterol compared with tiotropium at reducing activity-related breathlessness in patients with chronic obstructive pulmonary disease (COPD).<\/jats:p><jats:p>This was a randomised, double-blind, two-period crossover study including COPD patients with moderate to severe pulmonary impairment, lung hyperinflation at rest and a Mahler Baseline Dyspnoea Index &lt;8. Patients received 6\u2005weeks of tiotropium\/olodaterol 5\/5\u2005\u00b5g and tiotropium 5\u2005\u00b5g in a randomised order with a 3-week washout period. The speed for the 3-min CSST was determined for each patient such that an intensity of breathing discomfort \u22654 (\u201csomewhat severe\u201d) on the modified Borg scale was reached at the end of a completed 3-min CSST.<\/jats:p><jats:p>After 6\u2005weeks, there was a decrease in the intensity of breathlessness (Borg dyspnoea score) at the end of the 3-min CSST from baseline with both tiotropium (mean \u20130.968, 95% CI \u22121.238\u2013\u200a\u22120.698; n=100) and tiotropium\/olodaterol (mean \u22121.325, 95% CI \u22121.594\u2013\u200a\u22121.056; n=101). The decrease in breathlessness was statistically significantly greater with tiotropium\/olodaterol<jats:italic>versus<\/jats:italic>tiotropium (treatment difference \u22120.357, 95% CI \u22120.661\u2013\u200a\u22120.053; p=0.0217).<\/jats:p><jats:p>Tiotropium\/olodaterol reduced activity-related breathlessness more than tiotropium in dyspnoeic patients with moderate to severe COPD exhibiting lung hyperinflation.<\/jats:p>","DOI":"10.1183\/13993003.02049-2018","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T13:24:25Z","timestamp":1547731465000},"page":"1802049","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Dual bronchodilation with tiotropium\/olodaterol further reduces activity-related breathlessness<i>versus<\/i>tiotropium alone in COPD"],"prefix":"10.1183","volume":"53","author":[{"given":"Fran\u00e7ois","family":"Maltais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph-Leon","family":"Aumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Kirsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Nadreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemani","family":"Macesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xidong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis E.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"2024102100470018000_53.3.1802049.1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4104\/pcrj.2013.00025","article-title":"No room to breathe: the importance of lung hyperinflation in COPD","volume":"22","author":"Thomas","year":"2013","journal-title":"Prim Care Respir J"},{"key":"2024102100470018000_53.3.1802049.2","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200508-093DO"},{"key":"2024102100470018000_53.3.1802049.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00547.x"},{"key":"2024102100470018000_53.3.1802049.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00116004"},{"key":"2024102100470018000_53.3.1802049.5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.3.1168"},{"key":"2024102100470018000_53.3.1802049.6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/COPD.S32451","article-title":"Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial","volume":"7","author":"Beeh","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102100470018000_53.3.1802049.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01348-2016"},{"key":"2024102100470018000_53.3.1802049.8","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2017. http:\/\/goldcopd.org\/gold-2017-global-strategy-diagnosis-management-prevention-copd Date last accessed: October 26, 2017."},{"key":"2024102100470018000_53.3.1802049.9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/15412550903156317","article-title":"Paced-walk and step tests to assess exertional dyspnea in COPD","volume":"6","author":"Perrault","year":"2009","journal-title":"COPD"},{"key":"2024102100470018000_53.3.1802049.10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3109\/15412555.2012.674164","article-title":"Detecting improvements in dyspnea in COPD using a three-minute constant rate shuttle walking protocol","volume":"9","author":"Sava","year":"2012","journal-title":"COPD"},{"key":"2024102100470018000_53.3.1802049.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.01.006"},{"key":"2024102100470018000_53.3.1802049.12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10112662"},{"key":"2024102100470018000_53.3.1802049.13","doi-asserted-by":"publisher","DOI":"10.1136\/thx.47.12.1019"},{"key":"2024102100470018000_53.3.1802049.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2024102100470018000_53.3.1802049.15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035005"},{"key":"2024102100470018000_53.3.1802049.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201310-1863PP"},{"key":"2024102100470018000_53.3.1802049.17","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050655"},{"key":"2024102100470018000_53.3.1802049.18","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2807"},{"key":"2024102100470018000_53.3.1802049.19","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12142"},{"key":"2024102100470018000_53.3.1802049.20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rmed.2017.06.020","article-title":"Impact of LABA\/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysis","volume":"129","author":"Calzetta","year":"2017","journal-title":"Respir Med"},{"key":"2024102100470018000_53.3.1802049.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00124013"},{"key":"2024102100470018000_53.3.1802049.22","first-page":"758","article-title":"Efficacy of indacaterol\/glycopyrronium in patients with COPD who have increased dyspnea with daily activities","volume":"3","author":"Mahler","year":"2016","journal-title":"Chronic Obstr Pulm Dis"},{"key":"2024102100470018000_53.3.1802049.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.08.002"},{"key":"2024102100470018000_53.3.1802049.24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41533-016-0002-x","article-title":"Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies","volume":"27","author":"Ferguson","year":"2017","journal-title":"NPJ Prim Care Respir Med"},{"key":"2024102100470018000_53.3.1802049.25","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.01470.2005"},{"key":"2024102100470018000_53.3.1802049.26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12931-018-0721-3","article-title":"Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis","volume":"19","author":"Di Marco","year":"2018","journal-title":"Respir Res"},{"key":"2024102100470018000_53.3.1802049.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.00216501"},{"key":"2024102100470018000_53.3.1802049.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00136014"},{"key":"2024102100470018000_53.3.1802049.29","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.9901038"},{"key":"2024102100470018000_53.3.1802049.30","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.5.9804004"},{"key":"2024102100470018000_53.3.1802049.31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.chest.2018.02.020","article-title":"To improve COPD care: a new instrument is needed to assess dyspnea","volume":"154","author":"Mahler","year":"2018","journal-title":"Chest"},{"key":"2024102100470018000_53.3.1802049.32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.rmed.2016.11.011","article-title":"Long-term general and cardiovascular safety of tiotropium\/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease","volume":"122","author":"Buhl","year":"2017","journal-title":"Respir Med"},{"key":"2024102100470018000_53.3.1802049.33","first-page":"A3035","article-title":"Safety of tiotropium\/olodaterol in COPD: pooled analysis of three large, 52\u2013week randomized clinical trials","volume":"197","author":"Ferguson","year":"2018","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02049-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:33:45Z","timestamp":1740382425000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02049-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,28]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1183\/13993003.02049-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02049-2018","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]}}}